DLA Piper has advised Marinomed Biotech AG, a leading Austrian biotechnology business, on the sale of its Carragelose business to Unither Pharmaceuticals, a French contract development and manufacturing organization (CDMO). Carregelose is a sulphated polymer from red seaweed and a unique, broadly active virus and allergen-blocking compound.
Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the MarinosolvĀ® platform. The MarinosolvĀ® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange.
A multi-disciplinary team from DLA Piper’s Vienna office worked on the transaction led by Corporate partner Maria Doralt. The team also comprised partners Sabine Fehringer (IPT), Christian Temmel (Corporate), Marc Lager (Lit&Reg), Dimitar Hristov (Tax), and Stephan Nitzl. They were supported by counsel Christian Knauder-Sima, senior associate Eric Wingert, and junior associates Christian Scheucher and Madeleine Albers.
